Halozyme Therapeutics Inc (HALO)

[halofan]

While I am not versed in the technical aspects of these trials, from what I read of the excerpt from argenx, they were testing to see if the subcutaneous version of efgartigimod would work for this particular disease. So, to me. It would seem that the problem was with efgartigimod, and not Enhanze because Enhanze is not designed to cure anything and we know it delivers the various drugs effectively because of all the successful trials with so many different types of drugs.